Please ensure Javascript is enabled for purposes of website accessibility

CRISPR Gene-Editing Stocks Surge as Intellia Provides Updates on Treatment Candidates

By Mark Prvulovic - Updated Feb 11, 2020 at 12:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Preclinical results from two of the biotech's pipeline candidates look promising.

Intellia Therapeutics (NTLA 5.22%) is presenting positive new data regarding a pair of its promising gene-editing programs at a medical conference taking place in Banff, Canada. Investors applauded the news by bidding up shares of Intellia, and other major gene-editing stocks shot up as well.

The first of the candidates Intellia's researchers will report on, NTLA-5001, is a treatment for patients with acute myeloid leukemia (AML), a rare type of cancer that causes the bone marrow to produce abnormal white and red blood cells. The company will also be providing preclinical results regarding its treatment for hereditary angioedema (HAE), an autoimmune disorder that's characterized by excessive swelling in various parts of the body.

A person holding some scissors making a small cut of a genome.

Image source: Getty Images.

"We are observing very favorable preclinical data with our engineered T cells, and we are moving ahead with IND-enabling studies and manufacturing for NTLA-5001, to enable a regulatory submission in the first half of 2021," said Intellia President and CEO John Leonard.

Further details

Shares of Intellia were up 9.1% Monday, and other gene-editing stocks such as CRISPR Therapeutics and Editas Medicine rose by similar percentages. Although gene-editing biotechs often have some overlap in their treatment candidate portfolios (sickle-cell disease is one condition that most such companies are targeting), they still are at fairly early stages of research and clinical development.

As such, positive results regarding CRISPR/Cas9 gene-editing technology, even when they come from potential competitors, are seen as good news for companies throughout the niche.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Editas Medicine, Inc. Stock Quote
Editas Medicine, Inc.
EDIT
$13.47 (-0.22%) $0.03
Intellia Therapeutics Stock Quote
Intellia Therapeutics
NTLA
$53.41 (5.22%) $2.65
CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
CRSP
$66.96 (2.78%) $1.81

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.